Ascentage Pharma Group International logo

Ascentage Pharma Group International(AAPG)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$14.62
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for AAPG

11/13/2026: AAPG (1-star) is currently NOT-A-BUY. Pass it for now.

Ascentage Pharma Group International is a clinical-stage biotechnology company that develops targeted small-molecule therapies for cancers and hepatitis B. The company's primary strengths include its proprietary apoptosis-targeting platforms and the commercialization of its flagship drug, Olverembatinib. Its main growth opportunity lies in expanding global clinical approvals and advancing pipeline candidates like Lisaftoclax. Key risks involve clinical trial uncertainties, intense market competition, and ongoing net losses inherent to early-commercial biotech firms. The stock suits growth-oriented investors willing to accept high volatility, with close monitoring required for clinical readouts and regulatory updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers exposure to a rapidly expanding clinical pipeline and commercializing oncology assets with high addressable market potential.
Momentum investorMixed fitMomentum fit is conditional on positive clinical data readouts and upward price momentum signals.
Value investorWeak fitAs a pre-profit or early-commercial clinical biotech firm, it lacks traditional value metrics like positive earnings or P/E stability.
Dividend investorWeak fitThe company does not pay dividends, directing all capital toward clinical development and growth.
Low-risk investorWeak fitHigh clinical development risks and share price volatility make it unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience sharp price swings driven by clinical trial updates and market sentiment.
Valuation riskMedium / highValuations rely heavily on future clinical success and regulatory approvals rather than current earnings.
Competition risk (targeted oncology and kinase inhibitors)HighThe company faces intense competition from established pharmaceutical giants developing alternative oncology treatments.
Business qualityMediumWhile backed by strong scientific platforms, the business model remains exposed to clinical trial uncertainties.
Dividend incomeLow / noneNo dividend is paid, offering zero income return for investors.
Execution riskHighSuccessful commercial scaling and clinical execution are crucial for long-term viability.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.37B USD
Price to earnings Ratio -
1Y Target Price 44.5
Price to earnings Ratio -
1Y Target Price 44.5
Volume (30-day avg) 7.7K shares
Beta 0.77
52 Weeks Range 13.46 - 33.09
Updated Date 11/15/2026
52 Weeks Range 13.46 - 33.09
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.26

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 46.69%
Avg. Invested days 90
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 5.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
AAPG receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
AAPG has soft overall fundamentals (2 stars), with moderate financial health, weak growth momentum, and soft ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-198.2%), weak cash generation (FCF margin -215.2%), negative revenue growth (-43.1%).

Financial Health Rating

★★★★★
AAPG's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 32.8%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
AAPG's growth profile is soft, with the least-weak measure being revenue growth at -43.1% FY2025 versus FY2024. By comparison, while earnings growth (-198.2%, negative) and free-cash-flow growth (-785.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.0% (soft) and 77.3% of outstanding shares are publicly tradable (solid). Insider ownership is only 0.00%, which materially reduces the ownership score.

Top 5 Institutional Investors

Point72 Asset Management, L.P. 0.01%
Morgan Stanley - Brokerage Accounts 0.00%
Wells Fargo & Co 0.00%
EverSource Wealth Advisors, LLC 0.00%
UBS Group AG 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
AAPG generates approximately $764 of gross profit, $-2,111 of operating income, and $-2,152 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.56% (Tax Credit)

Quantitative Style Profile

★★★★★
AAPG has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product SalesCommercial revenue generated from approved pharmaceutical products such as Olverembatinib in select markets.The company earns initial commercial revenue from selling its approved cancer therapies.
Licensing and CollaborationUpfront payments, milestone fees, and royalties from biopharmaceutical partnerships.Partnership agreements provide supplementary financial inflows to support ongoing research.

Valuation

Trailing PE -
Forward PE 9.43
Enterprise Value 1.37B
Price to Sales(TTM) 2.12
Enterprise Value 1.37B
Price to Sales(TTM) 2.12
Enterprise Value to Revenue 14.2
Enterprise Value to EBITDA -
Shares Outstanding 93.39M
Shares Floating 72.17M
Shares Outstanding 93.39M
Shares Floating 72.17M
Percent Insiders -
Percent Institutions 0.04

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.